-4.97 -1.86%
Volume: 357,358

Featured Presentation

November 10, 2021 Annual Investor Conference 2021 Presentation
View this Presentation (PDF 10.63 MB)


Rockwell Automation and Cytiva collaborate to accelerate automation platforms in the biopharmaceutical industry

December 03, 2021

Companies plan to build an Automation and Digital Transformation Center
in Shanghai, China

MILWAUKEE, December 03, 2021 — Rockwell Automation, the world’s largest company dedicated to industrial automation and digital transformation, today announced that it has begun collaborating with Cytiva, a global life sciences leader, to accelerate the industry’s digital transformation. This new collaboration deepens Cytiva’s 2019 pledge to invest in China and also strengthens the relationship between Rockwell and Cytiva that has been in place since 2019. Cytiva joined the Rockwell Automation PartnerNetwork Program as an OEM Partner to help drive a best-in-class distributed control system offering.

Rockwell Automation and Cytiva will bring their combined expertise in biomanufacturing and automation to create an efficient, flexible, and scalable platform. As part of the collaboration, the companies are building an Automation and Digital Transformation Center, located inShanghai, to co-host demonstrations, trainings, and more.

Ian Shih, regional vice president, Greater China, Rockwell Automation, says: “Scalable and sustainable development is of the utmost importance to our companies and to the industry as a whole. Our combined solutions offer the flexibility to scale up for vaccine production or scale down to produce smaller batches of personalized medicines.”

Lihua Yu, General Manager, Greater China, Cytiva says: “As the industry moves toward more automated manufacturing solutions, together we can bring digital-oriented R&D and streamlined production to life not only in China, but throughout the world. Our joint work will accelerate the development and delivery of transformative medicines, reduce costs, and ultimately deliver more medicines to patients in need.”

Rockwell Automation and Cytiva will promote Cytiva’s Figurate automation platform in China, as well as globally. The suite of offerings by Rockwell will power Cytiva’s range of solutions from idea to injection. The collaboration enables stronger integration, data collection, and analysis. This results in a standardized manufacturing platform capable of core data management.

In addition, the two companies have established multiple centers, including the Testa Center in Uppsala, Sweden, to assist customers in their drug development process. They are exploring how to apply the Industrial Internet of Things (IIOT), Augmented Reality (AR) and other advanced technologies for connectivity across the manufacturing process. With innovative solutions for factory field management in progress, Rockwell Automation and Cytiva are establishing a promising future for digital solutions for biopharmaceutical companies, helping enhance training and efficiency for operators, improving speed of batch review, streamlining equipment management, and intensifying efficiency.

About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 24,500 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing The Connected Enterprise to life across industrial enterprises, visit

Mario R. Martin
Manager, Global Public Relations
Rockwell Automation

About Cytiva:
Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Learn more:

Iris Zhao
+ 021 6181 8278